Menu
Currency
GWAS Study

Genetic Variants Associated with Acamprosate Treatment Response in Alcohol Use Disorder Patients: A Multiple Omics Study.

Ho MF, Zhang C, Wei L et al.

35016259 PubMed ID
GWAS Study Type
442 Participants
40 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HM
Ho MF
ZC
Zhang C
WL
Wei L
ZL
Zhang L
MI
Moon I
GJ
Geske JR
SM
Skime MK
CD
Choi DS
BJ
Biernacka JM
OT
Oesterle TS
FM
Frye MA
SM
Seppala MD
KV
Karpyak VM
LH
Li H
WR
Weinshilboum RM
Chapter II

Abstract

Summary of the research findings

Background and purpose: Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety and those who relapsed, to determine whether those differences provide insight into variation in acamprosate treatment response phenotypes.

442 individuals

Chapter III

Study Statistics

Key metrics and study information

442
Total Participants
GWAS
Study Type
No
Replicated
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.